A clinical case of treatment of dedifferentiated retroperitoneal liposarcoma
https://doi.org/10.33667/2078-5631-2025-33-60-66
Abstract
Despite the low incidence of soft tissue sarcomas, providing care to patients with this condition is an important mission of current oncology. The high mortality rate among patients within the first year of diagnosis, as well as the low five-year survival rate, highlight the need for timely diagnosis and the implementation of modern anti-cancer drug therapies that have proven to be highly effective in clinical practice. This article presents a clinical case study of a patient with recurrent dedifferentiated retroperitoneal liposarcoma, evaluating disease progression and prognosis of disease
About the Authors
Yu. V. Batukhtina
Krasnoyarsk State Medical University named after professor V. F. Voyno-Yasenetsky; Krasnoyarsk Regional Clinical Oncology Center named after A. I. Kryzhanovsky
Russian Federation
Russian Federation
Batukhtina Yulia V., PhD Med, associate professor at Dept of Oncology and Radiation Therapy with a Postgraduate Course; head of Dept of Telemedicine Consultations
Krasnoyarsk
I. P. Safontsev
Krasnoyarsk State Medical University named after professor V. F. Voyno-Yasenetsky; Krasnoyarsk Regional Clinical Oncology Center named after A. I. Kryzhanovsky
Russian Federation
Russian Federation
Safontsev Ivan P., PhD Med, associate professor at Dept of Oncology and Radiation Therapy with a Postgraduate Course; deputy chief physician for Organizational and Methodological Work
Krasnoyarsk
T. E. Zabrodskaya
Krasnoyarsk State Medical University named after professor V. F. Voyno-Yasenetsky
Russian Federation
Russian Federation
Zabrodskaya Tatyana E., medical statistician of Organizational and Methodological Dept
Krasnoyarsk
D. V. Gavrilyuk
Krasnoyarsk State Medical University named after professor V. F. Voyno-Yasenetsky; Krasnoyarsk Regional Clinical Oncology Center named after A. I. Kryzhanovsky
Russian Federation
Russian Federation
Gavrilyuk Dmitry V., PhD Med, associate professor at Dept of Oncology and Radiation Therapy with a Postgraduate Course; oncologist at Emergency Dept
Krasnoyarsk
R. A. Zukov
Krasnoyarsk State Medical University named after professor V. F. Voyno-Yasenetsky; Krasnoyarsk Regional Clinical Oncology Center named after A. I. Kryzhanovsky
Russian Federation
Russian Federation
Zukov Ruslan A., Dr Med Sci (habil.), professor, head of Dept of Oncology and Radiation Therapy with a Postgraduate Course; chief physician
Krasnoyarsk
References
1. List of rare (orphan) diseases. Year of approval: 2025. https://minzdrav.gov.ru/documents/9824-perechen-redkih-orfannyh-zabolevaniy. Date of access: 10.10.2025. (In Russ.).
2. Kaprin A. D., Starinsky V. V., Shakhzadova A. O. et al. Malignant neoplasms in Russia in 2023 (incidence and mortality). M.: P. A. Herzen Moscow Oncology Research Institute – branch of the National Medical Research Center of the Ministry of Health of the Russian Federation; 2024. 276 p. (In Russ.).
3. Kaprin A. D., Starinsky V. V., Petrova G. V. The state of oncological care for the population of Russia in 2024. M.: P. A. Herzen Moscow Oncology Research Institute – branch of the National Medical Research Center of the Ministry of Health of the Russian Federation; 2025. 275 p. (In Russ.).
4. WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. Lyon (France): International Agency for Research on Cancer; 2020. (WHO classification of tumours series, 5 th ed. Vol. 3). https://publications.Iarc.fr/588/.
5. Sbaraglia M., Bellan E., Dei Tos A. P. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. Pathologica. 2021; 113 (2): 70–84. DOI: 10.32074/1591–951X-213
6. Comandone A., Petrelli F, Boglione A. et al. Salvage Therapy in Advanced Adult Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis of Randomized Trials. The Oncologist 2017; 22: 1518–1527.
7. Volkov A. Yu., Kozlov N. A., Nered S. N., Stilidi I. S., Stroganova A. M., Arkhiri P. P., Antonova E. Yu., Privezentsev S. A. Retroperitoneal dedifferentiated liposarcomas: semiquantitative assessment of the dedifferentiated component and prognosis. Archives of Pathology 2020, Vol. 82, No. 5, pp. 25–32. (In Russ.). https://doi.org/10.17116/patol20208205125
8. Clinical guidelines. Retroperitoneal non-organ sarcomas. Year of approval: 2024. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. https://cr.minzdrav.gov.ru/preview-cr/618_3. Date of access: 14.11.2025. (In Russ.).
9. Order of the Ministry of Health of Russia dated May 11, 2023 N 223n «On approval of standards of medical care for adults with soft tissue sarcomas.» https://bazanpa.ru/minzdrav-rossii-prikaz-n223n-ot11052023-h6023811/. Date of access: 15.10.2025. (In Russ.).
10. Egorenkov V. V., Bokhan A. Yu., Konev A. A. et al. Soft tissue sarcomas. RUSSCO practical recommendations, part 1.2. Malignant neoplasms 2024; 14 (3s2): 393–413. (In Russ.). DOI: https://doi.org/10.18027/2224-5057-2024-14-3s2-1.2-15
11. Volkov A. Yu., Nered S. N., Kozlov N. A., Stilidi I. S., Arkhiri P. P., Antonova E. Yu., Privezentsev S. A. Prognostic groups for retroperitoneal well-differentiated and dedifferentiated liposarcomas. Medical Council. 2021; (4S): 94–102. (In Russ.). DOI: 10.21518/2079–701X-2021–4S-94–102
12. Kolesnikov E. N., Maksimov R. A., Demidov S. I., Kozhushko M. A., Sanamyants S. V., Averkin M. A. Remote overall and relapse-free survival of patients with retroperitoneal non-organ liposarcomas. Modern problems of science and education. 2024. No. 4. URL: https://science-education.ru/ru/article/view?id=33581 (accessed: 12/18/2025). (In Russ.). DOI: https://doi.org/10.17513/spno.33581
13. Demetri G. D., Mehren M., Jones R. L. et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol; 34(8):786–793. DOI: 10.1200/JCO.2015.62.4734
14. Clinical guidelines. Soft tissue sarcomas. Year of approval: 2025. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. https://cr.minzdrav.gov.ru/preview-cr/515_3. Date of access: 14.11.2025. (In Russ.).
15. Kawai A., Araki N., Sugiura H. et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol. 2015; 16 (4): 406–416. DOI: 10.1016/S1470–2045(15)70098-7
16. Barone A., Chi D. C., Theoret M. R. et al. FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen. Clin Cancer Res. 2017; 23 (24): 7448–7453. DOI: 10.1158/1078–0432.CCR-17–0898
17. Le Cesne A., Blay J. Y., Cupissol D. et al. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. Ann Oncol. 2021; 32 (8): 1034–1044. DOI: 10.1016/j.annonc.2021.04.014
18. Italiano A., Toulmonde M., Cioffi A. et al. Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Ann Oncol. 2012; 23 (6): 1601–1607. DOI: 10.1093/annonc/mdr485
19. Fedenko A. A., Gorbunova V. A. Trabectedin: new possibilities of chemotherapy of disseminated soft tissue sarcoma. Вreast cancer. 2009: 617 p. (In Russ.).
20. Fedenko A. A., Tryakin A. A., Zhukova L. G. et al. National guidelines for drug treatment of individual malignant tumors. M: 2020. 408 p. (In Russ.).
21. Belitsky G. A., Kirsanov K. I., Lesovaya E. A. et al. Trabectedin – a DNA minor groove ligand. Advances in Molecular Oncology. 2015; 2: 41–49. (In Russ.).
22. D’Incalci M., Badri N., Galmarini C. M. et al. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer. 2014; 111 (4): 646–650. DOI: 10.1038/bjc.2014.149
23. Instructions for medical use of the medicinal product Yondelis (trabectedin). https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=abc18c75-60ae-4278-a726-8bf1d125ce2a. Date of access: 11.14.2025. (In Russ.).
24. Araki N., Takahashi S., Sugiura H. et al. Retrospective inter- and intra-patient evaluation of trabectedin after best supportive care for patients with advanced translocation-related sarcoma after failure of standard chemotherapy. Eur J Cancer. 2016; 56: 122–130. DOI: 10.1016/j.ejca.2015.12.014
25. Demetri G. D., von Mehren M., Jones R. L. et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016: 34 (8): 786–793.
26. Fabbroni C., Fucà G., Ligorio F. et al. Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated. Dedifferentiated Liposarcoma Treated with Trabectedin. Cancers (Basel); 13 (6): 1453. DOI: 10.3390/cancers13061453
27. Pautier P., Italiano A., Piperno-Neumann S. et al. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2022; 23 (8): 1044–1054. DOI: 10.1016/S1470–2045(22)00380-1
28. A randomised, multicenter phase-III study comparing doxorubicin (dox) alone versus dox with trabectedin (trab) followed by trab in non-progressive patients (pts) as firstline therapy, in pts with metastatic or unresectable leiomyosarcoma (LMS): Final results of the LMS-04 study Annals of oncology? Volume 34 – Issue S 2–2023 https://doi.org/10.1016/j.annonc.2023.09.1142
29. Gamboa A. C., Gronchi A., Cardona K. Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine. CA Cancer J Clin. 2020; 70 (3): 200–229. DOI: 10.3322/caac.21605
Review
For citations:
Batukhtina Yu.V., Safontsev I.P., Zabrodskaya T.E., Gavrilyuk D.V., Zukov R.A. A clinical case of treatment of dedifferentiated retroperitoneal liposarcoma. Medical alphabet. 2025;(33):60-66. (In Russ.) https://doi.org/10.33667/2078-5631-2025-33-60-66
Views:
179
JATS XML
Email this article 